Renal Biomarkers Market Size to Exceed USD 3,000.1 Mn by 2032

The Renal Biomarkers Market, estimated at USD 1,728.0 Mn in 2025, is expected to exhibit a CAGR of 8.2% and reach USD 3,000.1 Mn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

The key market players are focused on adopting growth strategies such as collaborations and acquisitions, which will drive the global renal biomarkers market. For instance, in September 2025, Baxter International Inc., a multinational healthcare company, announced a distribution agreement with bioMérieux, a multinational biotechnology company, for the NEPHROCLEARTM CCL14 diagnostic test. The NEPHROCLEARTM CCL14 test is currently in development for use in assessing the risk of developing persistent severe acute kidney injury (AKI). As part of the agreement, Baxter will be bioMérieux's exclusive distributor of the NEPHROCLEARTM CCL14 test in Europe and the U.S. following regulatory approval and launch in both markets. Baxter and bioMérieux will share in-country commercialization, while bioMérieux will retain control over the regulatory approval process. Incorporating new diagnostic products into Baxter's Acute Therapies portfolio advances the company’s efforts to support overall patient management by providing solutions that enable efficiencies in critical care.

Global Renal Biomarkers Market Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.

COVID-19 had a positive impact on the global renal biomarkers market. For instance, in August 2025, according to an article published in the journal Nature reviews of Nephrology, the article estimated approximately 20% of patients of U.S. on dialysis died within 1 month of SARS-CoV-2 infection — substantially higher than the risk of death associated with other infections or many cardiovascular events. Excess mortality among patients on maintenance dialysis was nearly 30% higher relative to preceding 5-year trends during the initial height of the pandemic in the U.S. and the U.K.

Global Renal Biomarkers Market: Key Developments

On April 28, 2025, The Fiscal Year 2025 (FY23) Defense Appropriations Act provides funding for the Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer. The managing agent for the anticipated funding opportunities is the CDMRP (Congressionally Directed Medical Research Programs) at the U.S. Army Medical Research and Development Command (USAMRDC). The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities.

In November 2025, Boditech Med, Inc., a pharmaceutical company that provides diagnostic solutions entered into a license agreement with SphingoTec GmbH, a biotechnology company, for the kidney function biomarker Proenkephalin A 119-159 (penKid). Under the terms of this agreement, Boditech Med has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma Point of Care platforms. SphingoTec has a monopoly on the penKid, a unique biomarker for real-time assessment of kidney function.

On January 5, 2025, Bruker Corporation, manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis, announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions, for bioimaging and high-content microscopy. This acquisition adds high-performance on-premise processing, secure storage and networking technology that complements Bruker’s advanced fluorescence microscopy imaging products, such as light-sheet and super-resolution microscopy products, which generate high information content.

Browse 31 Market Data Tables and 22 Figures spread through 145 Pages and in-depth TOC on “Global Renal Biomarkers Market”- Forecast to 2032, Global Renal Biomarkers Market, by Biomarker Type (Functional Biomarker (Serum Creatinine, Serum Cystatin C, Urine Albumin), Up-Regulated Proteins (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule 1, Interleukin 18), Others), By Technique (Enzyme Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay, Colorimetric Assay, Chemiluminescent Enzyme Immunoassay, Liquid Chromatography-Mass Spectrometry), By End User (Diagnostic Labs, Outpatient Clinics, Research Centers, Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa).

To know the latest trends and insights prevalent in this market, click the link below::

https://www.coherentmarketinsights.com/market-insight/renal-biomarkers-market-3551

Key Takeaways of the Global Renal Biomarkers Market:

The global renal biomarkers market is expected to exhibit a CAGR of 8.2% during the forecast period. The collaborators with emerging economies offers lucrative growth opportunities for players in the global renal biomarkers market. Advancement in technology have enabled the development of new and improved renal biomarker assays that offer greater sensitivity, accuracy, and precision. These advancements are expected to drive the renal biomarkers market growth.
Among technique, Enzyme Linked Immunosorbent Assay (ELISA) segment is expected to growth in the global renal biomarker segment over the forecast period. For instance, in October 2025, BioPorto A/S, announced it had showcased its NGAL (Neutrophil gelatinase-associated lipocalin) biomarker for acute kidney injury (AKI) research (clinical chemistry assay, ELISA kits, and antibodies) at booth #2734 during the world’s premier nephrology conference, ASN (American Society of Nephrology) Kidney Week, November 4, 2025, in Orlando, Florida (U.S.). The NGAL TestTM is CE (Conformité Européenne) marked and available for in vitro diagnostic use in the European Union; registered in several countries, and available for Research Use Only in the United States. The NGAL biomarker is one of six urinary biomarkers in the U.S. FDA's Center for Drug Evaluation and Research’s (CDER) kidney safety composite measure. CDER encourages safety biomarkers for monitoring drug-induced renal tubular injury in early clinical drug development.
Among biomarkers type, Functional Biomarkers segment is expected to hold a dominant position in the global renal biomarkers market during the forecast period and this is attributed to the technological advancements in the field of Renal Biomarkers Market. For instance, in September 2025, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases released its final report, which outlines a new race-free approach to diagnosing kidney disease. In the report, the NKF-ASN Task Force recommends the adoption of the new eGFR 2025 CKD EPI creatinine equation that estimates kidney function without a race variable. The task force also recommended increased use of cystatin C combined with serum (blood) creatinine, as a confirmatory assessment of GFR or kidney function. The final report, published online in the American Journal of Kidney Diseases (AJKD) and the Journal of the American Society of Nephrology (JASN),
Among region, North America is expected to be the dominant region in the global renal biomarkers market, owing to the increasing launch of products. For instance, in October 2025, Fresenius Medical Care North America (FMCNA), the renal care company, announced an innovative partnership with Livongo Health, Inc., the applied health signals company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD). The new partnership enables Fresenius Health Partners, a division of FMCNA, to better deliver targeted, real-time care coordination services through Livongo Whole Person for CKD.
Major players operating in the global renal biomarkers market include Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, Bioporto Diagnostics A/S, Astute Medical, Inc., Randox Laboratories, Sphingo Tec GmbH, Siemens Healthineers AG, Eli Lilly and Company, and Novartis AG.